HEALTH PROFESSIONAL · SOURCE READING

Bispecific T-cell engagers

Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Indolent, Recurrent B-Cell Non-Hodgkin Lymphoma / Treatment Options for Indolent, Recurrent B-Cell NHL

Bispecific T-cell engagers bind to CD20 (or CD19) and to CD3 to direct T cells to eliminate malignant B cells.[25,26] Similar to CAR T-cell therapy, almost one-half of patients who receive this therapy experience cytokine release syndrome.

Source links and citations

Continue within this section

Mosunetuzumab →Epcoritamab →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Independent clinical review pending · Not medical advice